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Although the role of genetic factors in the origin of Parkinson disease has long been disputed, several genes involved
in autosomal dominant and recessive forms of the disease have been localized. Mutations associated with early-
onset autosomal recessive parkinsonism have been identified in the Parkin gene, and recently a second gene, PARK6,
involved in early-onset recessive parkinsonism was localized on chromosome 1p35-36. We identified a family
segregating early-onset parkinsonism with multiple consanguinity loops in a genetically isolated population. Ho-
mozygosity mapping resulted in significant evidence for linkage on chromosome 1p36. Multipoint linkage analysis
using MAPMAKER-HOMOZ generated a maximum LOD-score of 4.3, with nine markers spanning a disease
haplotype of 16 cM. On the basis of several recombination events, the region defining the disease haplotype can
be clearly separated, by 25 cM, from the more centromeric PARK6 locus on chromosome 1p35-36. Therefore,
we conclude that we have identified on chromosome 1 a second locus, PARK7, involved in autosomal recessive,
early-onset parkinsonism.
Parkinson disease (PD [MIM 168600]) is a neurodege-
nerative disorder characterized by bradykinesia, resting
tremor, muscular rigidity, and postural instability. The
cerebral pathology includes loss of dopaminergic neu-
rons, in particular at the substantia nigra and cytoplas-
matic eosinophilic inclusions (i.e., Lewy bodies). The
role of genetic factors in the origin of PD has long been
disputed. However, several families segregating the dis-
ease as a dominant or recessive trait have been identified.
At present, four genes implicated in autosomal dominant
forms of parkinsonism have been identified or localized,
including the a-synuclein gene (Polymeropoulos et al.
1997), the ubiquitin carboxy-terminal hydrolase-L1
gene (Leroy et al. 1998), and two yet-unidentified
genes—PARK3 on chromosome 2p13 (Gasser et al.
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1998) and PARK4 on chromosome 4p14-16.3 (Farrer
et al. 1999). Until now, most mutations have been found
in the Parkin gene (Kitada et al. 1998) and have been
found to lead to a recessive form of juvenile parkinson-
ism (ARJP [MIM 600116]). The onset age may vary
from 20 to 65 years, but in most patients the onset is
at age !40 years (Lu¨cking et al. 2000). Parkinmutations
are estimated to explain up to 50% of familial patients
with ARJP (Lu¨cking et al. 2000). Recently, a new locus,
PARK6 (MIM 605909), involved in autosomal recessive
early-onset parkinsonism was localized on chromosome
1p35-36 in a single Italian family (Valente et al. 2001).
In the present report, we describe a family segregating
early-onset parkinsonism with multiple consanguinity
loops that we identified in a genetically isolated popu-
lation. We report the findings of a genome search using
homozygosity mapping in an effort to localize the gene
involved in the disease.
Patients were from a genetically isolated community
in the southwestern region of The Netherlands. The
study is part of a larger research program named “Ge-
netic Research In Isolated Populations” (GRIP). The iso-
lated population was founded ∼1750, by ∼150 individ-
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Figure 1 Pedigree of family with autosomal recessive early-onset parkinsonism, and haplotypes of marker loci spanning the linked region
on chromosome 1p36. To protect patient confidentiality, a diamond symbol has been used to mask the sex of all family members. Individuals
VI-2, VI-3, and VII-1–VII-7 were examined clinically. Black symbols indicate definitely affected individuals; black bars denote the disease-
associated haplotype.
uals. The scientific protocol of GRIP has been approved
by the Medical Ethical Committee of the Erasmus Med-
ical Center Rotterdam. From the population, initially
three patients (VII-2, VII-3 and VII-7) diagnosed with
early-onset parkinsonism were ascertained, including
two affected siblings and one apparently sporadic pa-
tient (fig. 1). The patients and their first-degree relatives
were personally examined by the research physician, a
neurologist, and a clinical geneticist. Clinical diagnosis
of parkinsonism required the presence of at least two of
the three cardinal signs (i.e., resting tremor, bradykine-
sia, and muscular rigidity) and absence of atypical fea-
tures and of signs of involvement of other neurological
systems (pyramidal, cerebellar, or autonomic). The ex-
trapyramidal signs were evaluated by Hoehn-Yahr stag-
ing (HY) (Hoehn and Yahr 1967) and the Unified Par-
kinson’s Disease Rating Scale (UPDRS; maximum of
motor subscalep 108) (Fahn et al. 1987). Furthermore,
structural and functional brain-imaging studies were
performed. The clinical examinations of available rela-
tives revealed a fourth affected individual (VII-6), who
was not known to have the diagnosis of parkinsonism.
The clinical details of the four affected subjects are
reported in table 1. Onset of symptoms was at age 40
years in three subjects (VII-2, VII-3, and VII-7). The
fourth affected individual (VII-6), who was age 40 years
at the time of the clinical examination, was newly di-
agnosed with parkinsonism and could not indicate the
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Table 1




THERAPY HY UPDRS OTHER CHARACTERISTICS
Time of
Study Onsetb RT PT B R P AS
VII-2 50 40 X X X X Untreated II 29 Psychotic episodes
VII-3 48 31 X X X X X X Pergolide III 57 Neurotic signs, blepharospasm
VII-6 40 NA X X X X Untreated III 22 Neurotic signs
VII-7 38 27 X X X X X L-dopa/IDD, entacapone III 42 Wearing-off, dyskinesias, off dystonia
a RT p resting tremor; PT p postural tremor; B p bradykinesia; R p muscular rigidity; P p loss of postural reflexes; AS p asymmetric
onset of symptoms.
b NA p not available.
age at onset of the disease. None of the patients exhibited
atypical features or signs of involvement of additional
neurological systems. The parkinsonian signs responded
well to therapy with L-dopa or dopamine agonists in
two patients (VII-3 and VII-7); at the time of clinical
examination, the two other patients still had not been
treated with antiparkinsonian drugs. One patient (VII-
7) showed motor fluctuations of “wearing-off” type, L-
dopa–induced dyskinesias in the “on” phase, and “off”-
phase dystonia (i.e., laterocollis). Mild blepharospasm
was present in patient VII-3, who receives dopamine-
agonist therapy. Tendon reflexes in lower limbs were
brisk in three of the patients (VII-3, VII-6, and VII-7).
Babinski sign was absent. Two of the patients also
showed neurotic signs, and one had suffered from psy-
chotic episodes. In all patients, the progression of disease
was slow. Structural brain images were unremarkable,
in agreement with the diagnosis of idiopathic parkin-
sonism. Brain single-positron–emission computed to-
mography with dopamine-transporter tracer, performed
in patients VII-2 and VII-3, showed severe abnormalities
consistent with presynaptic dysfunction of nigrostriatal
dopaminergic systems. Autopsy data are not available.
At the time of clinical examination, the ages of unaf-
fected individuals VII-1, VII-4 and VII-5 were 54, 50,
and 46 years, respectively.
The genealogical history of the isolate has been com-
puterized as far back as 1750. Although the patients
were not aware of consanguinity in their family, the ped-
igree of each of the two sibships showed multiple con-
sanguinity loops (fig. 1). The pedigree is drawn on the
basis of the two shortest consanguinity loops for both
parent pairs (VI-1/V-2 and VI-2/VI-3), which links the
two sibships to a common ancestor six generations ago.
However, other connections between the sibships exist,
including a second loop linking VI-1 and V-2 to a com-
mon ancestor, who is also related to VI-2.
The pedigree structure is consistent with an autosomal
recessive mode of inheritance, and the kindred therefore
was considered to be suitable for homozygositymapping
(Lander and Botstein 1987). For all patients and avail-
able first-degree relatives, genomic DNA was isolated
from peripheral blood, according to the method de-
scribed by Miller et al. (1988). For the systematic ge-
nome scan, short tandem-repeat polymorphisms
(STRPs) from the ABI PRISM Linkage Mapping Set
MD-10 (Applied Biosystems) were used. Additional
markers for fine-mapping and the PARK6 region were
obtained from the Ge´ne´thon and Marshfield (Center for
Medical Genetics, Marshfield Medical Research Foun-
dation) genetic-marker sets. Marker order and distances
were obtained from the Marshfield (Center for Medical
Genetics, Marshfield Medical Research Foundation) in-
tegrated linkage map. Markers were amplified from ge-
nomic DNA, according to methods specified by theman-
ufacturers. PCR products were pooled and loaded onto
an ABI377 automated sequencer (filter set D; 5% de-
naturing FMC LongRanger acrylamide gel), and data
were analyzed by ABI GENESCAN3.1 and ABI GENO-
TYPER2.1 software.
In the initial screens, only three definitely affected in-
dividuals (VII-2, VII-3, and VII-7) were genotyped. We
first tested for linkage of our family to known PD loci
(Polymeropoulos et al. 1997; Gasser et al. 1998; Kitada
et al. 1998; Leroy et al. 1998; Farrer et al. 1999), using
STRPs from the ABI PRISM Linkage Mapping Set MD-
10. At chromosome 4q22, the markers D4S414 and
D4S1572 were assessed; at chromosome 4p14, markers
D4S419 and D4S405; at chromosome 4p14-16.3, mark-
ers D4S419 and D4S1592; at chromosome 6q25.2-q27,
markers D6S1581 and D6S264; and, at chromosome
2p13, markers D2S337 and D2S2368. The analysis of
the markers flanking the known PD genes did not show
evidence for homozygosity, indicating that the disease in
the family cannot be explained by one of these known
genes (data not shown). We then performed a systematic
genome screen. LOD scores were generated by the pro-
gram MAPMAKER-HOMOZ (Kruglyak et al. 1995),
under the assumptions of equal recombination for males
and females, autosomal recessive inheritance, and gene
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Table 2
Genotypes of Affected Individuals, for




VII-2 VII-3 VII-6 VII-7
D1S199 2 5 3 5 2 5 3 4
D1S483 1 1 1 2 1 1 2 2
D1S478 3 5 1 3 3 5 2 3
D1S2828 4 1 4 5 4 1 4 3
D1S2732 2 4 2 3 2 4 1 4
D1S2702 2 4 2 3 2 4 4 1
D1S2734 5 4 5 5 5 4 4 1
D1S2885 4 1 4 2 4 1 1 3
D1S247 4 2 1 6 4 2 3 5
SOURCE.—Valente et al. (2001).
a Order is according to the Marshfield
(Center for Medical Genetics, Marshfield
Medical Research Foundation) integrated
linkage map.
frequency .004. In the initial genome screen, the family
structure used in the analysis is depicted in figure 1, and
allele frequencies were estimated on the basis of theDNA
of 51 spouses of patients participating in the various
studies in GRIP. The three individuals included in the
initial screen (VII-2, VII-3, and VII-7) were homozygous
for six markers, located on chromosomes 1, 5, 11, 17,
and 21. Only for the chromosome 1 region, two adjacent
markers (D1S468 and D1S214) were found to be ho-
mozygous in all patients, leading to a maximum LOD
score of 2.8.
The newly diagnosed patient (VII-6) was identified
after this initial screen and was typed, together with
unaffected first-degree relatives (VI-2, VI-3, VII-1, VII-
4, and VII-5), only for the five regions at which the first
three patients were homozygous.
Homozygosity remained only for markers on chro-
mosomes 1, 5, and 17. On chromosomes 5 and 17, ho-
mozygosity was found with very-frequent (34% and
42%, respectively) alleles of the markers D5S1981 and
D17S944. For closely linked (i.e., !10 cM distant) mark-
ers, all four patients were heterozygous, indicating that
the observed alleles for these markers could be identical
by state (IBS). In contrast, the population frequency of
the homozygous allele at D1S468 was 9%. The chances
that the homozygous allele in our distantly related pa-
tients is IBS are very small. In addition, all four patients
were homozygous for the flanking marker D1S214, in-
dicating that the alleles were most likely identical by
descent. We therefore saturated the region surrounding
D1S468 and D1S214 with 13 additional markers and
found that all patients were homozygous for 9 of the
markers studied, whereas the unaffected parents and two
unaffected siblings were all either heterozygous or non-
carriers of the disease haplotype (fig. 1). When LOD
scores for the disease haplotype were calculated, equal
allele frequencies for eachmarker were assumed, because
population allele frequencies were not available. Pene-
trance was assumed to be 100% by age 40 years. The
most conservative analysis—that is, under the assump-
tion that there is a second-degree relationship between
the parents of the sibships—resulted in a maximummul-
tipoint LOD score of 4.3. Subsequent haplotype analysis
showed homozygosity of all four patients, for a region
of ∼16 cM on the sex-averaged linkage map. The first
recombination events were observed for marker D1S243
on the telomeric side in individual VII-6 and for marker
D1S244 on the centromeric side in individual VII-3.
Because of Valente et al.’s (2001) recent report of link-
age of an early-onset autosomal recessive form of par-
kinsonism to chromosome 1p35-36, we investigated
whether we could exclude linkage to the PARK6 region
in the family that we studied; we tested nine markers
from the PARK6 region (table 2). The patients in this
family showed no homozygosity at any of these markers.
The PARK6 critical region, between markers D1S483
and D1S247, is localized 25 cM centromeric of our
critical region. Considering the evidence that the critical
region in the family that we studied does not overlap
with the region encompassing the PARK6 gene identified
by Valente et al. (2001) and taking into account the
recommendations that Lander and Kruglyak (1995)
have made with regard to the reporting of linkage find-
ings, we report a significant linkage finding for the pres-
ence, on chromosome 1p, of a second locus for auto-
somal recessive early-onset parkinsonism; and we
propose to name it “PARK7.”
Both PARK6 (Valente et al. 2001) and PARK7 were
identified by homozygosity mapping. Although this is a
very powerful approach in consanguineous pedigrees
(Lander and Botstein 1987), some possible methodo-
logical problems recently have been raised in articles
published in the Journal (Miano et al. 2000). Miano et
al. (2000) have shown that patients may be homozygous
for large regions by chance—in particular if there are
multiple loops in the pedigree, such as occur in the ped-
igree that we studied. However, our most conservative
analysis, based on an analysis assuming a second-degree
relationship, still yielded a LOD score 14. In addition,
the fact that the affected individuals from the two sib-
ships share an identical homozygous haplotype, whereas
none of the unaffected first-degree relatives was ho-
mozygous for this haplotype, makes a false-positive find-
ing less likely.
Using homozygosity mapping, we have identified a
third locus for autosomal recessive early-onset parkin-
sonism: PARK7. Similar to what has been reported in
other studies of early-onset parkinsonism and Parkin
mutations (Lu¨cking et al. 2000), the disease in the pa-
tients of the family that we studied is characterized by
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a slow progression. Dystonic features, including bleph-
arospasm and laterocollis, and brisk tendon reflexes
have also been found in patients with Parkin mutations
(Abbas et al. 1999; Lu¨cking et al. 2000; Tassin et al.
2000). PARK7 is the second locus, in the chromosome
1p36 region, involved in autosomal recessive, early-on-
set parkinsonism. The region defining the disease hap-
lotype can be clearly separated from that of the more
centromeric PARK6 locus. Although the genomic se-
quence of the critical region is far from complete and
many gaps remain, a first analysis of the Project Ensembl
and Human Genome Project Working Draft at UCSC
databases showed that inside the critical region 25
genes are located, including 7 genes with an unknown
function. Possible candidate genes are the gene encoding
the vesicle-associated membrane protein 3 (VAMP3) and
the gene encoding protein kinase C, zeta (PRKCZ). Telo-
meric of D1S243, a ubiquitin-conjugating enzyme has
been localized. Although this would be an obvious can-
didate, its location is outside the candidate region. The
observation, on chromosome 1p, of two closely linked
loci for early-onset parkinsonism raises the question
whether there might have been a duplication of this chro-
mosomal region during evolution; however, comparison
of the gene contents from the PARK6 and PARK7 critical
regions and the syntenic region in the mouse does not
support this idea.
Recessive mutations in the Parkin gene have been
shown to be a common cause of early-onset parkinson-
ism (Lu¨cking et al. 2000). Our findings and those of
Valente et al. (2001) strongly suggest there may be other
recessive mutations, in at least two unidentified genes
involved in the disease. Analysis of additional families
with early-onset parkinsonism lacking Parkinmutations
will reveal the importance of these two new loci for
early-onset parkinsonism.
The frequency of recessive mutations in early-onset
parkinsonism may even have masked the genetic origin
of PD for a long time, since familial aggregation and the
identification of consanguinity require extensive genea-
logical research. Therefore, it remains to be determined
whether these common recessive mutations are involved
in late-onset forms of the disease as well. Studies of in-
bred and/or isolated populations such as GRIP may
therefore help to further dissect the pathogenesis of PD.
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